Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Antimicrob Agents Chemother. 2020 May 21;64(6):e00754-20. doi: 10.1128/AAC.00754-20. Print 2020 May 21.

Markus Hoffmann^{1

2}, Simon Schroeder^{3

4}, Hannah Kleine-Weber^{1

2}, Marcel A Müller^{3

4

5}, Christian Drosten^{3

4}, Stefan Pöhlmann^{6

2}

¹ Deutsches Primatenzentrum-Leibniz Institute for Primate Research, Göttingen, Germany.
² Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.
³ Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany.
⁴ German Centre for Infection Research, associated partner Charité, Berlin, Germany.
⁵ Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov University, Moscow, Russia.
⁶ Deutsches Primatenzentrum-Leibniz Institute for Primate Research, Göttingen, Germany [email protected].

No abstract available

Keywords: COVID-19; SARS-CoV-2; TMPRSS2; coronavirus.

Publication types